CompoundAtlas
Sign in

CJC-1295

65
evidence score
peptide
Gray Market
106 studies
Modified GRF 1-29Mod GRF 1-29CJC1295+1 more

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Two forms exist: with DAC (Drug Affinity Complex) extending half-life to 6–8 days via albumin binding, and without DAC (Modified GRF 1-29) with a 30-minute half-life mimicking natural pulsatile GH release. Used to stimulate GH and IGF-1 for muscle growth, fat loss, recovery, and anti-aging. Commonly combined with ipamorelin for synergistic GH pulse amplification.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

No formal trials

Last Sync

Feb 19, 2026

Last Reviewed

Not reviewed yet

Physician Notes

The DAC version provides sustained GH elevation vs the acute pulse of non-DAC (Mod GRF 1-29). Some practitioners prefer the more physiologic pulse of the non-DAC version combined with ipamorelin.

FDA Status:Restored to 503A compounding list.

Monitoring

  • IGF-1 q3mo
  • Fasting glucose/HbA1c

Contraindications

  • Active malignancy
Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical
200 mcg
100 mcgRange300 mcg
Frequency1–3x/day without DAC; 1–2x/week with DAC

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~30 min without DAC; 6–8 days with DAC
Onset15–30 minutes post-injection (GH pulse)
DurationGH pulse 2–3 hours; IGF-1 elevation sustained with DAC
Routes
subcutaneous
intramuscular

Evidence Score

65
Level B — Moderate
106 studies indexed
Scoring Factors
Volume(24%)~41/100
Quality(24%)~40/100
Sample Size(12%)~87/100
Consistency(14%)~87/100
Replication(8%)~87/100
Recency(18%)~87/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

CJC-1295 is currently categorized as a peptide compound.

Evidence is moderate (65/100): promising signal from 106 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

GHRH receptor agonist on pituitary somatotrophs; stimulates pulsatile GH release and downstream IGF-1 production

Practical Context

Strongest current signals

  • Level C: This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
  • Level C: The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.
  • Level C: Growth hormone-releasing hormone and its analogues in health and disease.

Compound Profile